L'tude a montr que l'obxlimab produisait une amlioration clinique rapide, forte et soutenue, y compris une rmission clinique complte, chez la plupart des patients atteints de ML–IgG4 active
Read more »
Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology
Study found obexelimab produced rapid, strong, and sustained clinical improvement, including complete clinical remission, in most patients with active IgG4–RD
Results support the [...] Read more »
Medela Concludes Global Breastfeeding Symposium with Key Takeaways in Lactation Science to Inform Clinical Practice
Switzerland, Baar, June 27, 2023 (GLOBE NEWSWIRE) — Medela, the brand trusted by millions of moms*, concluded its 16th Global Breastfeeding and Lactation Symposium, focused on advancing lactation science to [...] Read more »
NRx Pharmaceuticals, Lotus Pharmaceuticals e Alvogen Inc. anunciam colaboração para desenvolver e comercializar o NRX-101
- NRx Pharmaceuticals, Lotus Pharmaceuticals e Alvogen iro colaborar no desenvolvimento e comercializao futuros de NRX–101 para tratar [...] Read more »
NRx Pharmaceuticals, Lotus Pharmaceuticals und Alvogen Inc. kündigen Zusammenarbeit zur Entwicklung und Vermarktung von NRX-101 an
- NRx Pharmaceuticals, Lotus Pharmaceuticals und Alvogen kooperieren bei der weiteren Entwicklung und Vermarktung von NRX–101 gegen [...] Read more »
NRx Pharmaceuticals, Lotus Pharmaceuticals et Alvogen Inc. annoncent leur collaboration pour le développement et la commercialisation du NRX-101
- NRx Pharmaceuticals, Lotus Pharmaceuticals et Alvogen collaborent au dveloppement et la commercialisation sur les marchs mondiaux du [...] Read more »
NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101
- NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen to collaborate on the further development and commercialization of NRX–101 for suicidal treatment–resistant bipolar depression (S–TRBD) for global markets
Read more »
Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)
Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4–RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs
[...] Read more »Two Female Scientists Win this year’s King Faisal Prize
Jeddah, Saudi Arabia, Jan. 04, 2023 (GLOBE NEWSWIRE) — Two women scientists were announced King Faisal Prize for Medicine and Science laureates for 2023: a Covid–19 vaccine developer and a nanotechnology scientist. Six others [...] Read more »
Minovia Therapeutics Reports First Clinical Data Demonstrating Disease-Modifying Efficacy and Safety of Mitochondrial Augmentation Therapy in Pediatric Patients with Primary Mitochondrial Diseases
First in human clinical study provides proof–of–concept for mitochondrial augmentation therapy platform, which enables use of healthy mitochondria to improve mitochondrial function and mitigate effects of [...] Read more »